Anixa is focused on the treatment and prevention of cancer.

Anixa Biosciences, Inc. is a clinical stage biotechnology company focused on the treatment and prevention of cancer.


Therapeutics

CAR-T

We are developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer.

Vaccines

Breast Cancer Vaccine

We are developing a revolutionary vaccine technology focused on treating and preventing multiple forms of breast cancer.

Ovarian Cancer Vaccine

Using a similar mechanism of action as our breast cancer vaccine technology, we are developing a vaccine against ovarian cancer.

Lung, Colon, & Prostate Cancer Vaccines

We have commenced a cancer vaccine discovery program utilizing the same mechanism as our breast and ovarian cancer vaccines, to develop additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate.

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus

Latest News & Events

Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial

Read More...

Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium

Read More...

Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival

Read More...

Stock Data

View Investors Relations
Nasdaq: ANIX
Price
Change